首页> 美国卫生研究院文献>other >Autologous hematopoietic stem cell transplantation in lymphoma patients is associated with a decrease in the double strand break repair capacity of peripheral blood lymphocytes
【2h】

Autologous hematopoietic stem cell transplantation in lymphoma patients is associated with a decrease in the double strand break repair capacity of peripheral blood lymphocytes

机译:淋巴瘤患者的自体造血干细胞移植与外周血淋巴细胞双链断裂修复能力降低相关

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Patients who undergo autologous hematopoietic stem cell transplantation (aHCT) for treatment of a relapsed or refractory lymphoma are at risk of developing therapy related- myelodysplasia/acute myeloid leukemia (t-MDS/AML). Part of the risk likely resides in inherent interindividual differences in their DNA repair capacity (DRC), which is thought to influence the effect chemotherapeutic treatments have on the patient’s stem cells prior to aHCT. Measuring DRC involves identifying small differences in repair proficiency among individuals. Initially, we investigated the cell model in healthy individuals (primary lymphocytes and/or lymphoblastoid cell lines) that would be appropriate to measure genetically determined DRC using host-cell reactivation assays. We present evidence that interindividual differences in DRC double-strand break repair (by non-homologous end-joining [NHEJ] or single-strand annealing [SSA]) are better preserved in non-induced primary lymphocytes. In contrast, lymphocytes induced to proliferate are required to assay base excision (BER) or nucleotide excision repair (NER). We established that both NHEJ and SSA DRCs in lymphocytes of healthy individuals were inversely correlated with the age of the donor, indicating that DSB repair in lymphocytes is likely not a constant feature but rather something that decreases with age (~0.37% NHEJ DRC/year). To investigate the predictive value of pre-aHCT DRC on outcome in patients, we then applied the optimized assays to the analysis of primary lymphocytes from lymphoma patients and found that individuals who later developed t-MDS/AML (cases) were indistinguishable in their DRC from controls who never developed t-MDS/AML. However, when DRC was investigated shortly after aHCT in the same individuals (21.6 months later on average), aHCT patients (both cases and controls) showed a significant decrease in DSB repair measurements. The average decrease of 6.9% in NHEJ DRC observed among aHCT patients was much higher than the 0.65% predicted for such a short time frame, based on ageing results for healthy individuals.
机译:接受自体造血干细胞移植(aHCT​​)治疗复发或难治性淋巴瘤的患者有发展与治疗相关的骨髓增生异常/急性髓细胞白血病(t-MDS / AML)的风险。部分风险可能在于其DNA修复能力(DRC)的固有个体差异,据认为这会影响aHCT之前化学疗法对患者干细胞的作用。测量DRC涉及识别个体之间维修能力的微小差异。最初,我们研究了健康个体(原代淋巴细胞和/或淋巴母细胞系)中的细胞模型,该模型适用于使用宿主细胞激活测定法来测定遗传确定的DRC。我们提供的证据表明,DRC双链断裂修复的个体差异(通过非同源末端连接[NHEJ]或单链退火[SSA])可以更好地保存在非诱导的原代淋巴细胞中。相反,诱导增殖的淋巴细胞是分析碱基切除(BER)或核苷酸切除修复(NER)所必需的。我们确定健康个体的淋巴细胞中的NHEJ和SSA DRC都与供体的年龄成反比,表明淋巴细胞中DSB的修复可能不是恒定的特征,而是随着年龄的增长而降低(〜0.37%NHEJ DRC /年)。为了研究aHCT前DRC对患者预后的预测价值,我们将优化的分析方法应用于淋巴瘤患者的原代淋巴细胞分析,发现后来发展出t-MDS / AML的患者(病例)在他们的DRC中无法区分来自从未开发过t-MDS / AML的控件。但是,当在aHCT之后不久对同一人进行DRC调查(平均21.6个月后)时,aHCT患者(包括病例和对照组)的DSB修复指标均明显下降。根据健康个体的衰老结果,在aHCT患者中观察到的NHEJ DRC平均下降6.9%,远高于在如此短的时间范围内预测的0.65%。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号